Elimusertib enhances cytotoxic effects of conventional chemotherapy and sensitizes to radiation in preclinical Ewing sarcoma models

Read full text Summarise with VIRAT
Authors: Leonhard Koch, Maximilian Kerkhoff, Maximilian Bretschneider, Samet Dayi, Pauline Plaumann, Bahareh Sadeghi, Emma Maaßen, Emilia Hillesheim, Marc Kuballa, Christiane Schaefer, Daniel Rauh, Susanne Grünewald
+3 more Sebastian Bauer, Cläre von Neubeck, Uta Dirksen
Cited by: 0
References: 62

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Ewing Sarcoma (EwS) is a highly aggressive malignancy predominantly affecting young individuals, with poor prognosis in metastatic or relapsed cases. This study investigates the therapeutic potential of ataxia telangiectasia and Rad3-related protein (ATR) inhibition using the selective small-molecule inhibitor elimusertib, both as a monotherapy and in combination with cytotoxic drugs or radiotherapy. Elimusertib significantly inhibited cell proliferation and induced apoptosis in EwS cell lines. In a chorioallantoic membrane (CAM) model, elimusertib suppressed tumor initiation and reduced tumor volume. Notably, elimusertib exhibited synergistic effects with standard chemotherapeutics and radiation, enhancing antitumor efficacy. These preclinical findings suggest that ATR inhibition by elimusertib may enhance current EwS therapies and enable dose reduction of cytotoxic drugs. Further clinical evaluation is warranted to validate these findings and explore elimusertib’s translational potential in EwS treatment.

Fields of Study & Subjects

Sarcoma Diagnosis and Treatment PARP inhibition in cancer therapy Cancer-related Molecular Pathways

Publication details

Journal / source
Scientific Reports
Volume
16
Issue
1
Publication date
27 March 2026
Language
EN